A phase III trial found that women with luminal A subtype of breast cancer had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy. In contrast, patients with non-luminal A subtypes who received chemotherapy were 50% less likely to have their disease recur in 10 years.
A phase III trial found that capecitabine improved disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy. The study showed a 30% reduced risk of disease recurrence compared to standard therapy.
UC Davis researchers have made significant progress in tumor treatment by combining guided ultrasound with nanoparticle chemotherapy, resulting in improved survival and consistent cure rates. The technique allows for complete destruction of tumors without thermal damage to surrounding tissue.
Breast cancer patients treated with anthracycline-based chemotherapy experienced lower verbal memory and default mode brain network connectivity compared to non-chemotherapy groups. Cognitive dysfunction was also elevated in both treatment groups, highlighting the need for further research into chemotherapy-related neurotoxic effects.
Researchers at National Research Tomsk State University found that neoadjuvant chemotherapy can stimulate evolution of the tumor, leading to resistance and metastasis. The study analyzed biopsies from women with breast cancer before and after surgery, revealing a 23% increase in new tumor formation.
A recent Yale University study found that black women with stage I-III cancer are less responsive to neoadjuvant chemotherapy compared to other racial groups. Despite presenting with more advanced-stage and aggressive tumors, the findings suggest biologic differences or disparities in treatment may be contributing factors.
A study published in Human Pathology found that lung cancer patients without the retinoblastoma tumor suppressor protein (pRB) experience significantly improved survival rates when undergoing chemotherapy. The absence of pRB was detected in 15% of patients, with a 92% 5-year survival rate compared to 49% for those with the protein.
A new study reveals that chemotherapy-induced hearing loss in pediatric brain tumor survivors can lead to significant neurocognitive deficits, including intelligence, executive function, and verbal reasoning skills. Children who received radiation therapy and developed hearing loss are at particularly high-risk for these deficits.
Researchers at the University of Georgia have discovered a mechanism that could lead to better ovarian cancer treatment by targeting chemoresistance. The RGS10 protein impacts the effectiveness of chemotherapy, and manipulating its expression can improve treatment outcomes.
Scientists at MIT have found a mechanism by which cancer cells develop resistance to chemotherapy drugs. The MK2 pathway takes over when p53 is disabled, allowing cells to continue dividing even with extensive DNA damage. Measuring the levels of specific RNAs could help predict patients' response to chemotherapy.
Researchers report that up to half of surgical site infections and over a quarter of infections after cancer chemotherapy are caused by resistant bacteria. The study predicts that reducing antibiotic efficacy could lead to 120,000 more infections and 6,300 infection-related deaths annually in the USA.
Researchers at VCU Massey Cancer Center found that depleting CHD4 protein makes AML cells more susceptible to chemotherapy agents, reducing DNA damage repair and tumor-forming properties.
Researchers develop new targeted delivery method using silk sponge to reduce chemotherapy's toxic effects on children with neuroblastoma. The approach slows tumor growth and reduces systemic toxicity, offering a promising alternative to traditional chemotherapy.
A major study published in the New England Journal of Medicine has identified a 21-gene test that can determine which breast cancer patients can safely avoid chemotherapy. The test, called Oncotype DX Recurrence Score, analyzes tumor samples and assigns scores between 0-100, indicating the risk of cancer recurrence.
Researchers found that adding hormonal treatment during chemotherapy reduced the risk of premature ovarian failure by 45% and increased pregnancy rates among young breast cancer patients. The use of LHRHa could be a potential standard strategy to preserve ovarian function and fertility in hormone receptor positive breast cancers.
Researchers found that patients with lower baseline microbial diversity are more likely to develop infections during chemotherapy. Monitoring the microbiome could help doctors predict infection risk and reduce antibiotic overuse.
Researchers have found three new drug-like compounds that target a protein responsible for chemotherapy resistance in cancers, offering hope for improved treatment options. The compounds have shown promise in re-sensitizing resistant cancer cells to chemotherapy, improving the odds of survival for prostate cancer patients.
A study of 44,044 Medicare patients with early-stage breast cancer found that the 21-gene recurrence score assay was associated with decreased chemotherapy use in high-risk patients and increased use in low-risk patients. The genetic test appeared to influence chemotherapy use regardless of age.
Researchers found that patients with acute myeloid leukemia (AML) who retained genetic mutations after chemotherapy were more likely to relapse and die. This approach to genetic profiling could help predict prognosis and determine treatment response, potentially improving outcomes for AML patients.
Researchers at VIB and KU Leuven found that inhibiting PHD1 prevents p53 activation, leading to improved response to chemotherapy in colorectal cancer cells. This discovery offers new therapeutic potential for increasing sensitivity to chemotherapeutic treatments.
Researchers discovered that treating tumors with chemotherapy can trigger a response in the immune system, leading to tumor growth. By combining chemotherapy with an immune-blocking drug, they found that this response could be slowed, potentially preventing tumor regrowth.
A study published in the Journal of American Geriatrics Society found that chemotherapy's effectiveness in prolonging life for older adults with most types of cancer is reduced for women over 80 with breast cancer. However, combining chemotherapy with another treatment may improve mortality risk reduction for this age group.
Researchers discovered that CA125-negative tumor cells have an enhanced ability to repair their DNA and resist programmed cell death, making them dangerous. Combining chemotherapy with birinapant significantly improved disease-free survival in laboratory models of human ovarian cancer.
A study published in JAMA Oncology found that chemotherapy was associated with worse quality of life near death for patients who could still perform many life functions. The researchers concluded that chemotherapy use may be unnecessary and potentially harmful for patients with progressive metastatic disease.
Researchers have developed a new drug, CCT245737, that blocks cancer's escape route from chemotherapy, boosting its effectiveness in treating lung and pancreatic cancers. The drug, a CHK1 inhibitor, demonstrates significant anti-cancer activity when combined with chemotherapy in mice.
The trial showed that early FDG-PET-positive patients benefit from intensification of chemotherapy, leading to improved progression-free survival rates. However, omitting involved-node radiotherapy in early PET-negative patients did not demonstrate non-inferiority to the standard treatment in terms of progression-free survival.
Researchers at Cancer Research UK have identified a protein called Bcl-xL that helps cancer cells survive chemotherapy. Combining drugs targeting Bcl-xL with taxanes showed increased killing of cancer cells in the lab. This combination could improve treatment for patients receiving taxanes and reduce side effects.
Researchers found that a silver coating on catheters breaks down chemotherapy drugs, reducing treatment effectiveness. In contrast, graphene was shown not to react with the drugs, making it a promising alternative for medical equipment coatings.
A study of 197 patients with breast cancer found that more selective use of biomarker testing could save up to $117 million annually. Testing larger excisional biopsies instead of reflexively testing smaller core biopsies would help pick up tumors eligible for targeted therapy, reducing unnecessary costs.
Researchers found that graphene prevents damage to chemotherapy drugs and reduces potential for catheters breaking, potentially improving treatment efficacy. Graphene's biocompatibility and low toxicity make it a promising alternative coating material.
A study has identified a possible new combination chemotherapy regimen for patients with advanced metastatic castrate-resistant prostate cancer. The treatment, combining cabazitaxel and carboplatin, significantly extended progression-free survival by 2.3 months compared to single-agent therapy.
Researchers at MD Anderson Cancer Center have identified a biomarker that may boost the response to chemotherapy in patients with ovarian cancer. The study found that miR-506 was associated with improved responses to chemotherapy drugs cisplatin and olaparib, leading to better overall survival.
A phase 1b study has shown impressive response rates of 60-75% in patients with untreated non-small cell lung cancer treated with chemotherapy and an anti-PD-L1 agent. The combination therapy was well-tolerated, with no unexpected toxicities.
Researchers found that blocking immune-suppressing cells allows chemotherapy to destroy prostate tumors in mouse models, achieving near complete remission. This novel combination therapy may have broader applications for other cancer types due to its effectiveness against metastatic and unresponsive cancers.
Women with breast cancer who follow a physical exercise program during chemotherapy experience less fatigue, nausea, and pain. The study found that both moderate and low-intensity exercise programs significantly reduced the need for dose adjustments in chemotherapy treatment.
A study has identified molecular changes that occur in tissue after chemotherapy in ovarian cancer patients. The researchers found that these changes could be potential targets for new, more personalized drugs. The findings have the potential to advance treatments for ovarian cancer.
Oncologists welcome gene expression profiling tests as an added tool in deciding whether women with early-stage breast cancer should have chemotherapy. However, they have significant reservations about the cost of the test and whether it is being overused and used for the right patients.
The use of the 21-gene recurrence score assay increased from 1.1% to 10.1% among Medicare beneficiaries diagnosed with breast cancer between 2005 and 2009. The majority of tests were performed in patients with intermediate-risk disease, and rates of chemotherapy remained similar during this period.
A study published in The New England Journal of Medicine found that adding goserelin to chemotherapy regimens can significantly reduce the risk of early menopause and improve fertility in young breast cancer patients. Women who took goserelin had a higher pregnancy rate and were more likely to deliver healthy babies.
Researchers found that patients who received chemotherapy after bladder cancer surgery had improved overall survival rates compared to those who underwent surgery alone. The study analyzed over 5,600 patients and demonstrated a significant reduction in mortality risk.
The study, which analyzed data from the National Cancer Data Base, found that 59% of women who received pre-surgery chemotherapy had breast conservation therapy. Women with larger tumors were also more likely to opt for pre-surgery chemotherapy and lumpectomy versus mastectomy.
Researchers from Brigham and Women's Hospital discovered that targeting cancer cells immediately after chemotherapy can make them more vulnerable to treatment. The 'one-two punch' approach involves administering two drugs simultaneously or sequentially, increasing the effectiveness of cancer therapy.
Two major studies strengthen the case for abiraterone as a treatment option for men with advanced prostate cancer. The trials found that receiving abiraterone before chemotherapy significantly extended men's lives by an average of four months, compared to those who did not receive it.
A new study published in Journal of Clinical Oncology finds that ultrasound can help surgeons decide whether to remove only a few or all underarm lymph nodes from breast cancer patients who have received chemotherapy, reducing the risk of complications and saving healthcare costs.
A study found that multiplexed genetic screening for EGFR and ALK gene rearrangements followed by molecularly-guided treatment is cost-effective compared to standard chemotherapy. The approach offers better outcomes in terms of quality-adjusted life years gained and life-years, making it a valuable option for patients with NSCLC.
Fox Chase researchers discovered that pancreatic cancer cells sidestep chemotherapy by hijacking the vitamin D receptor, a key mechanism driving chemotherapeutic effectiveness against pancreatic cancer. The findings raise hopes for developing new treatments that can selectively kill cancer cells while leaving healthy cells unharmed.
A study from Boston Children's Hospital and Dana-Farber Cancer Institute found that an existing epigenetic drug can increase the effectiveness of chemotherapy for patients with non-small-cell lung cancer (NSCLC) who have BRG1 or EGFR mutations. This breakthrough suggests a new approach to precision medicine in cancer treatment.
Researchers found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The study demonstrates the use of nanotechnology to repurpose existing chemotherapy drugs as effective agents against chemoresistant cancer stem cells.
A study found that entecavir significantly reduced the incidence of hepatitis B virus (HBV)-related hepatitis and HBV reactivation among patients receiving rituximab-based chemotherapy. The rates were lower in the entecavir group compared to the lamivudine group, with significant reductions in HBV-related complications.
Research shows adding chemotherapy drug carboplatin or blood vessel-targeting drug bevacizumab to standard preoperative chemotherapy increases pathologic complete response rates for women with basal-like triple-negative breast cancer. The drugs also showed benefits in certain gene signatures associated with aggressive disease.
A team of researchers has discovered a way to make triple-negative breast cancer cells susceptible to chemotherapy by inhibiting the HIF protein network. The study found that HIF inhibitors can decrease tumor size and prevent relapse in mice, offering new hope for treatment-resistant patients.
Researchers have developed a new technique to wrap chemotherapy drugs in fatty covers called liposomes, reducing heart damage and improving cardiac function. The study found that the group receiving Myocet had better diastolic and systolic function compared to conventional doxorubicin, with less fibrosis development.
Breast cancer patients undergoing chemotherapy and immediate breast reconstruction are at risk of thrombotic complications, which can delay or modify reconstructive plans. In some cases, these complications require anticoagulation therapy and may necessitate additional surgeries.
A £600,000 grant from Cancer Research UK will fund a research study investigating the efficacy of BTK inhibiting drugs in treating mantle cell lymphoma. The trial will compare these new drugs to standard chemotherapy and aim to improve life expectancy and quality of life for patients.
A novel combination therapy using low-dose chemotherapy with an antiangiogenic treatment, 3TSR, improved survival rates in an animal model of ovarian cancer. The treatment resulted in tumor regression, improved blood flow, and more efficient delivery of chemotherapy drugs with reduced side effects.
Researchers at Ohio State University have discovered a promising therapy combining an oncolytic virus with doxorubicin to treat advanced or recurrent ovarian cancer. The treatment showed significant antitumor activity in animal models, increasing survival and inducing programmed cell death in cancer cells.
A recent study published in the British Journal of Surgery found that extending surgical resection after two cycles of chemotherapy may be beneficial for some pediatric patients with hepatoblastoma. The research, conducted at Children's Hospital Los Angeles, suggests a potential reduction in complications from chemotherapy.
Research at Children's Hospital Los Angeles found that obese patients with acute lymphoblastic leukemia are more than twice as likely to have minimal residual disease, a strong predictor of long-term survival and disease recurrence. The study suggests modifying chemotherapy regimens for obese patients may improve outcomes.
A Dartmouth study found that Diffuse Optical Spectroscopic Tomography (DOST) imaging can accurately predict which patients will respond well to neoadjuvant chemotherapy, enabling earlier and more effective treatment. This breakthrough could significantly improve disease-free survival rates for breast cancer patients.
A study published in Journal of Clinical Oncology found that the 2005 Medicare law had no significant impact on reducing chemotherapy drug costs, contradicting economists' expectations. Instead, cancer care costs skyrocketed during the decade after the law passed.